Newport Beach
Wegovy Weight Loss in Newport Beach, CA
When the FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021, it was a major shift in obesity treatment. In the SELECT trial of about 17,500 adults with heart disease and extra weight, Wegovy led to about 20% fewer heart attacks, strokes and deaths from heart disease. At Adonis Saremi, MD, Newport Beach patients access a physician-supervised Wegovy program built around this medication’s extraordinary clinical profile.
When the FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in 2021, it was a major shift in obesity treatment. In the SELECT trial of about 17,500 adults with heart disease and extra weight, Wegovy led to about 20% fewer heart attacks, strokes and deaths from heart disease. At Adonis Saremi, MD, Newport Beach patients access a physician-supervised Wegovy program built around this medication’s extraordinary clinical profile.
What Makes Wegovy Clinically Different
Wegovy delivers semaglutide 2.4 mg via once-weekly subcutaneous injection, a dose specifically optimized for chronic weight management, higher than the 0.5 to 2 mg range used for diabetes. The STEP 1 trial showed 14.9 percent average weight loss versus 2.4 percent on placebo over 68 weeks. People regained about two-thirds of the weight they had lost within a year of stopping (STEP 1 extension). This underscores the importance of physician-planned maintenance.
The Evidence Behind Wegovy
- STEP 1 (2021). 14.9 percent average weight loss versus 2.4 percent placebo over 68 weeks in non-diabetic patients.
- SELECT trial (2023). 20 percent reduction in major adverse cardiovascular events in overweight adults with heart disease and without diabetes.
Is Wegovy the Right Program for You in Newport Beach?
- Adults in Newport Beach with a BMI of 30-plus, or 27-plus with hypertension, dyslipidemia, or another qualifying condition, who want FDA-approved chronic weight management therapy
- Patients who have tried dietary and lifestyle interventions seriously without adequate results and are ready for a pharmaceutical approach backed by landmark clinical evidence
- Those who want a Wegovy program actively managed with proper titration, lab monitoring, and dietary integration, rather than only a prescription and a monthly refill
- Patients across Newport Beach and Orange County looking for a physician who can contextualize Wegovy within their full health picture.
The SELECT Trial Changes the Clinical Calculus
For Newport Beach patients with heart disease and extra weight, Wegovy is also a cardiovascular intervention with FDA backing, not just a weight loss medication. Dr. Adonis Saremi’s Internal Medicine board certification means he evaluates this dimension with the clinical depth it warrants.
Start your Wegovy program in Newport Beach. Call (949) 288-3135 or book your consultation online today.
Frequently Asked Questions
How does Wegovy differ from Ozempic?
Both contain semaglutide, but Wegovy uses the higher 2.4 mg dose specifically approved for chronic weight management. Ozempic is approved for type 2 diabetes at doses up to 2 mg.
What results can I realistically expect?
The STEP 1 trial showed average weight loss of 14.9 percent. Individual outcomes depend on adherence, lifestyle factors, and baseline health status.
What happens if I stop taking Wegovy?
Weight regain is the expected clinical outcome. Our program builds a structured maintenance phase into every patient’s plan from day one.
Coming from Irvine or elsewhere in Orange County
Dr. Saremi’s Newport Beach office is at 4695 MacArthur Court, Suite 1100, a short drive from Irvine, Costa Mesa and Corona del Mar.
Most of your care happens by video and secure messaging, so you can be seen from anywhere in California. Premium members can also book their in-person visits at this office.